Salute e Benessere
Oncology Molecular Diagnostics Market to Reach US$ 6.46 Billion by 2033, Driven by Precision Oncology, and Accelerating Biomarker-Based Therapies - According to DataM Intelligence
The transformation of cancer care toward personalized therapies is significantly increasing the demand for molecular testing platforms. Cancer treatment decisions are now routinely anchored in , such as , and emerging biomarkers like , and tumor mutational burden (TMB).
By technology type, the market is dominated by , owing to its affordability, high-throughput screening capabilities, and routine integration into hospital laboratories for actionable biomarker detection. However, , supported by the industry's shift toward multi-gene panels, whole-genome sequencing (WGS), and liquid biopsy-based solutions. In situ hybridization (ISH) and other platforms continue to provide value in targeted diagnostics and histopathology-guided testing.
On the basis of products, , driven by the recurring nature of consumable usage in PCR and NGS workflows. Instruments-including automated sequencing systems and digital PCR platforms-remain essential capital investments for advanced oncology research centers. Software is rapidly becoming indispensable, with AI-driven genomic analysis, variant interpretation tools, and clinical decision-support platforms streamlining the complexities of multi-omic data.
(
By application, the oncology molecular diagnostics market spans a broad landscape of high-burden cancers.
, driven by HER2 amplification and BRCA mutation testing, represents a significant share of the global diagnostic volume.
continues to be one of the most dynamic areas, with molecular panels essential for identifying biomarkers such as EGFR mutations, ALK and ROS1 rearrangements, and PD-L1 expression supporting immunotherapy decisions.
are increasingly reliant on genomic profiling to guide precision therapies.
(including AML, ALL, and lymphomas) are rapidly transitioning toward NGS-based minimal residual disease (MRD) monitoring, further elevating the demand for high-sensitivity molecular assays.
Liver cancer, cervical cancer, and other tumor types continue to expand the market footprint as global screening initiatives and early-detection programs intensify.
Hospitals remain the leading end-user segment, driven by the integration of molecular diagnostics into pathologist workflows and multidisciplinary cancer care protocols.
Clinical laboratories are scaling their capabilities with advanced automated platforms, particularly in the U.S.,
Europe , and Japan , where adoption of NGS-based panels and liquid biopsy solutions is accelerating.
Specialty oncology centers and research institutes represent another growing market, propelled by their increased involvement in clinical trials, biomarker validation studies, and precision-medicine research.
The Oncology Molecular Diagnostics Market features a competitive environment led by global innovators such as , , , , , , , , , and . These companies continue to drive innovation across PCR kits, NGS panels, digital PCR systems, and companion diagnostics (CDx).
FDA approvals remain a key growth accelerator for oncology molecular diagnostics. In recent years, the U.S. FDA has approved several landmark tests that reinforce the importance of molecular diagnostics in cancer care:
These regulatory movements are reshaping treatment patterns by aligning drug approvals directly with advanced diagnostics, enabling faster clinical integration and broader patient access.
The oncology pipeline is expanding rapidly, with more than 2,000 active clinical trials requiring biomarker-based screening and genomic profiling.
Notable pipeline directions influencing diagnostics demand include:
The convergence of diagnostics with therapeutic innovation is expected to significantly expand oncology testing volumes globally throughout 2025–2033.
With global cancer incidence projected to exceed 30 million cases annually by 2040, healthcare systems are pivoting toward earlier identification, accurate mutation detection, and real-time monitoring. Governments and private health systems are increasing investments in genomic infrastructure, molecular testing automation, reimbursement frameworks, and national cancer-mapping initiatives.
Asia-Pacific remains the fastest-growing region, driven by expanding genomic testing capabilities in China , India , Japan , and South Korea . North America continues to lead in adoption, with strong clinical demand, higher reimbursement levels, and rapid integration of CDx partnerships. Europe exhibits steady growth through precision-health initiatives and improved NGS accessibility.
DataM Intelligence is a global market research and consulting firm delivering actionable insights across healthcare, biotechnology, pharmaceuticals, and life sciences industries. With continuous database updates, in-depth competitive intelligence, and 360-degree market coverage, DataM Intelligence supports strategic decision-making for industry leaders worldwide.
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn, and Facebook.
Sai Kiran
DataM Intelligence 4market Research LLP
Ground floor, DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad , Telangana 500039
+1 877-441-4866
Sai.k@datamintelligence.com
Logo: https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/oncology-molecular-diagnostics-market-to-reach-us-6-46-billion-by-2033--driven-by-precision-oncology-and-accelerating-biomarker-based-therapies---according-to-datam-intelligence-302618368.html